212 Pb ontuxizumab conjugate - AREVA Med/Morphotek

Drug Profile

212 Pb ontuxizumab conjugate - AREVA Med/Morphotek

Alternative Names: 212-Pb ontuxizumab conjugate - AREVA Med/Morphotek; 212-Pb radioimmunotherapy - AREVA Med/Morphotek; Alpha radioimmunotherapy - AREVA Med/Morphotek; Lead-212 radioimmunotherapy - AREVA Med/Morphotek

Latest Information Update: 28 Apr 2016

Price : $50

At a glance

  • Originator AREVA Med; Morphotek
  • Class Drug conjugates; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 31 Mar 2016 Preclinical trials in Solid tumours in USA (Parenteral)
  • 31 Mar 2016 AREVA and Morphotek agree to evaluate the safety and efficacy profile of ontuxizumab conjugated with lead-212 (212Pb) in USA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top